Cuprina Holdings (CUPR) received FDA 510(k) clearance for its MEDIFLY Maggots wound care product. The June 15th announcement marks the first FDA-cleared maggot debridement therapy using the Lucilia cuprina species.
Company shares surged 111.84% on Monday to close at $8.41. This rally followed a 64.7% gain on Friday after the company regained Nasdaq listing compliance.
The stock fell more than 22% in after-hours trading following the massive rally.